Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proportion of hepatocellu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2007-09, Vol.110 (5), p.1059-1067
Hauptverfasser:	Thomas, Melanie B., Chadha, Romil, Glover, Katrina, Wang, Xuemei, Morris, Jeffrey, Brown, Thomas, Rashid, Asif, Dancey, Janet, Abbruzzese, James L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology chemotherapy Diarrhea - virology Drug Administration Schedule EGFR erlotinib Erlotinib Hydrochloride Exanthema - chemically induced Fatigue - chemically induced Female Gastroenterology. Liver. Pancreas. Abdomen HCC hepatocellular hepatoma Humans Immunohistochemistry Kaplan-Meier Estimate Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism signal transduction Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!